Novo Nordisk A/S (NYSE:NVO) Shares Bought by Redhawk Wealth Advisors Inc.

Redhawk Wealth Advisors Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 12.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,361 shares of the company’s stock after purchasing an additional 2,406 shares during the period. Redhawk Wealth Advisors Inc.’s holdings in Novo Nordisk A/S were worth $1,837,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NVO. Wolff Wiese Magana LLC lifted its holdings in Novo Nordisk A/S by 25,350.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 3,054 shares of the company’s stock valued at $263,000 after purchasing an additional 3,042 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in shares of Novo Nordisk A/S by 52.7% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 785 shares of the company’s stock worth $68,000 after purchasing an additional 271 shares during the last quarter. Park Avenue Securities LLC increased its stake in Novo Nordisk A/S by 7.4% in the fourth quarter. Park Avenue Securities LLC now owns 102,657 shares of the company’s stock valued at $8,831,000 after purchasing an additional 7,103 shares during the last quarter. Peoples Financial Services CORP. boosted its stake in Novo Nordisk A/S by 9.4% in the 4th quarter. Peoples Financial Services CORP. now owns 8,449 shares of the company’s stock worth $727,000 after buying an additional 727 shares during the last quarter. Finally, Pines Wealth Management LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $331,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $82.99 on Thursday. The stock has a market capitalization of $372.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a one year low of $80.05 and a one year high of $148.15. The company’s 50-day simple moving average is $99.26 and its 200-day simple moving average is $118.18. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.